Ben Venue Laboratories Issues Voluntary Recall Of Acetylcysteine Solution - - BioPharm International

ADVERTISEMENT

Ben Venue Laboratories Issues Voluntary Recall Of Acetylcysteine Solution



Ben Venue Laboratories has issued a nationwide voluntary patient level recall of Acetylcysteine Solution 10%, USP, Lot 2005479 after the discovery of a single visible glass particle in a vial. There have been no complaints or adverse events related to a piece of glass in vials of this lot. All other product parameters were within specifications, according to a company statement. The recall is limited to a single lot number.

Acetylcysteine is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretion. Acetylcysteine, administered orally, is indicated as an antidote to prevent or lessen hepatic injury which may occur following the ingestion of a potentially hepatotoxic quantity of acetaminophen.

Source: Ben Venue Laboratories

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

NIH Seeks to Improve Vaccine Response with New Adjuvants
September 30, 2014
New Report Details Players and Pipelines in the Biosimilar Space
September 30, 2014
Baxter International Plans to Open R&D Center for Baxalta
September 30, 2014
FDA Releases First-Ever Purple Book for Biosimilar Characterization
September 26, 2014
FDA and NIH Win Award for IP Licensing of Meningitis Vaccine
September 26, 2014
Author Guidelines

Click here